Objective: In sub-Saharan Africa, many patients initiate antiretroviral therapy (ART) at CD4 þ cell counts much lower than those recommended in national guidelines. We examined program-level and contextual-level factors associated with low median CD4 þ cell count at ART initiation in populations initiating ART.
Introduction
Efforts to scale-up access to HIV care and treatment have been successful at initiating large numbers of patients on antiretroviral therapy (ART). In sub-Saharan Africa, the estimated number of persons on ART increased from 100 000 persons in 2003 to 3.9 million by the end of 2009, reaching an estimated 37% of those in need of ART [1] . Despite these successes, there remain persistent challenges to optimizing the success of HIV care and treatment scale-up in resource-limited settings. Among the most important challenges are very high rates of late ART initiation (i.e., in the advanced stages of HIV disease) [2, 3] , which is associated with early mortality after initiation of ART [4, 5] . A three-fold to four-fold higher mortality rate has been reported in the first year after ART initiation in resource-limited compared with resource-rich settings [6] , and high mortality rates have also been noted among persons enrolled in care in the period prior to ART initiation among those who are eligible for ART [2] . In addition to diminishing the potential successes of ART scale-up, late ART initiation also adds significant burden and costs to care [7] and missed opportunities for secondary HIV prevention due to late diagnosis [1, [8] [9] [10] .
With few exceptions, national guidelines in the subSaharan African region during 2004-2009 specified ART eligibility for patients with CD4
þ cell counts less than 200 cells/ml [11] . However, most patients initiate ART at substantially lower CD4 þ cell counts [2, 4, 6, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] , often with advanced clinical stages [28] . Further, there is substantial variability in the CD4
þ cell count at ART initiation across clinics and settings. For example, in an analysis from the ART-LINC collaboration, which included 19 967 patients from 27 centers in sub-Saharan Africa, Latin America, and Asia, the median CD4 þ cell count at ART initiation was 114 cells/ml (range across centers 61-181) among patients in sub-Saharan Africa [17] . WHO recently issued new HIV care and treatment guidelines for resource-limited settings recommending initiation of ARTat CD4 þ cell counts substantially higher than most current national guidelines [29] .
The reasons for late ART initiation are complex and multidimensional, and likely include factors at the contextual level (e.g., urban/rural, testing coverage, levels of stigma, and HIV knowledge), program level (e.g., clinic patient load, clinic burden of sick patients, staffing level, clinic policies, and practices such as provision of peer/adherence support), and individual level (e.g., sociodemographic, health beliefs, depression, social support, and substance use). The objective of this analysis was to identify factors at the program and contextual levels that are associated with low median CD4 þ cell count at ART initiation in cohorts from several countries in sub-Saharan Africa.
Methods
We used quarterly aggregate monitoring and evaluation (M&E) indicator data from HIV care clinics in eight sub-Saharan African countries (Ethiopia, Kenya, Lesotho, Mozambique, Nigeria, Rwanda, South Africa, and Tanzania) that received support from ICAP at Columbia University (www.columbia-icap.org) via the US Government's President's Emergency Plan for AIDS Relief (www.pepfar.gov) initiative. The use of data for this study was approved as nonhuman subjects research by the US Centers for Disease Control and Prevention (CDC) and the Institutional Review Board of Columbia University Medical Center.
Aggregate patient data Aggregate data included PEPFAR program M&E indicators that were routinely collected for M&E purposes [30] . Such aggregate data on patients initiating ART were manually tallied from paper-based systems (e.g., from pre-ART/ART registers and national forms) that were maintained by site staff. Data were reported per site per quarter on cohorts of patients initiating ART in a given 3-month period. Information on each cohort included the number of ART patients aged 6 years and above (cohort size), the number with a CD4
þ cell count at ART initiation, and the median CD4
þ cell count at ART initiation, which served as the outcome variable in this analysis.
Program-level data
Data on program-level and site-level characteristics were gathered via routinely conducted, structured site surveys completed through in-person queries of site staff. Site surveys were conducted in June 2007, December 2007, and July 2008. Site and program characteristics included the following: geographic setting (urban/rural), type of facility (primary, secondary, tertiary), availability of voluntary counseling and testing (VCT), prevention of mother-to-child transmission (PMTCT), and tuberculosis (TB) treatment services (onsite, offsite, not available at facility), availability of CD4 þ cell count testing (onsite or offsite), most common entry point into care at the site (VCT, PMTCT or labor and delivery, TB program, inpatient ward, outpatient clinic), inquiry about HIV status of family members of index patients and referral for testing, availability of supportive services such as outreach for patients who miss visits (none, outreach for ART patients only, or for both pre-ART and ART patients), presence of a peer educator program, and availability of adherence support services [number of different types adherence support services available (0-3, 4, 5, 6-12)]. Other cohort-level and program-level characteristics included the cumulative number of patients enrolled in care, the ratio of cumulatively enrolled to the number of patients cumulatively enrolled in care, and the clinical provider-to-patient ratio (e.g., physicians, clinical officers, and nurses), with cumulatively enrolled patients in the denominator.
The definition of urban and rural was determined locally using the categorizations of the Central Statistics Office or other national authority that determines the official category of a location. Broadly speaking, urban clinics were those in settings that were officially designated to be a city, with city administration and political bodies, or were located in big and small towns, peri-urban areas, growth points, and mining communities. Clinics in rural areas were those located in a village, subsistence farming areas, as well as large-scale and small-scale commercial farming areas. 
Contextual-level characteristics

Study sample and inclusion criteria
A total of 287 sites in 31 regions of the eight countries had patients who initiated ART during the study period (May 2004 to July 2008) were included in this analysis. Of these, 11 did not report data on cohorts of patients initiating ART, and additional nine sites did not report program-level data from the site survey available. The final sample in this analysis included 267 sites, where a total of 1690 3-month cohorts initiated ART during the study period, representing 121 504 patients aged 6 years and older. Cohort information from these 267 sites was combined with time-updated program-level data from site surveys according to the date during which cohort initiated ART and with contextual-level information from the DHS surveys.
Low median CD4
R cell count at antiretroviral therapy initiation (outcome) Three-month cohorts with median CD4 þ cell counts in the lowest quartile (<111 cells/ml) were classified as having low median CD4
þ cell counts at ART initiation. Among all 1690 3-month cohorts, the median proportion of patients in the cohort who had a CD4 þ count test result at ART initiation was 93% [interquartile range (IQR) 78-100]. We repeated our analysis excluding cohorts in which less than 75% of patients initiating ART had a baseline CD4 þ cell count, and the results were not altered. Analyses presented here include all 1690 cohorts.
Statistical methods
Univariate/bivariate analyses We used generalized linear mixed models to examine factors associated with low CD4
þ cell count at ART initiation among 3-month cohorts of patients who started ART. As the site surveys were repeated at different time points, program-level variables were treated as timedependent according to the quarter in which a given cohort initiated ART. Bivariate associations between hypothesized predictors and low cohort median CD4 þ cell counts were examined using chi-squared P values and crude odds ratios, accounting for within site clustering effects.
Multivariate analyses
We used generalized linear mixed models to examine the program-level and contextual-level factors that were independently associated with low cohort median CD4 þ cell count at ART initiation. After checking for linearity in the log odds, contextual-level factors were modeled continuously. All variables that were associated with the outcome at a ¼ 0.20 in bivariate analysis were examined in multivariate models that controlled for calendar time of ART initiation. A backward stepwise method was used, with final models including all factors significant at a ¼ 0.05. We used SAS Version 9.2 (Cary, North Carolina, USA), PROC GLIMMX for all statistical analyses.
Results
Sample description
The 267 sites reported cohort data on 1690 3-month cohorts, representing 121 504 patients who initiated ART during the study period (Table 1) . Sixty percent of the sites were in urban settings, representing 67% of the cohorts and 85% of the patients initiating ART. Ninetyfive percent of the sites were in either secondary (55%) or primary (40%) care facilities. Nearly 65% of patients initiated ART in the upper quartile of cohort size (i.e., 25% of cohorts accounted for 65% of patients). Eighty-six 
Median CD4
R cell count across cohorts at antiretroviral initiation Figure 1 shows the distribution of the median CD4 þ cell count at ART initiation for the 1690 cohorts of patients initiating ART. The median CD4 þ cell count across the 1690 cohorts initiating ARTwas 136 cells/ml and a lower quartile of median was 111 cells/ml. The majority of cohorts had median CD4 þ cell counts less than 200 cells/ ml, with 25% of the 121 504 patients initiating ART in cohorts with median CD4 þ cell counts in the lowest quartile of 111 cells/ml or less. (13) 161 (10) 8906 (7) a Sites categorized according to the time when the first cohort initiated antiretroviral therapy (ART) at the site. Program-level factors In crude analyses ( Table 3 shows contextual-level factors for the 31 subnational regions according to the tertiles of the distribution for each variable as of [2003] [2004] [2005] . In univariate analyses, the proportion of households in regions with electricity and piped water were significantly associated with lower median cohort CD4
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Contextual-level factors
þ cell count at ART initiation (Table 3) . Cohorts initiating ART in regions with HIV prevalence rates of 19% or more were less likely to have low median CD4 þ cell counts (OR 0.53; 95% CI 0.32-0.90). A higher proportion of persons in the region who believed that 'limiting themselves to one HIV-uninfected sexual partner reduces HIV risk' was significantly associated with low cohort median CD4 þ cell count at ART initiation (OR tertile 2 vs. 1 2.1; 95% CI 1.2-3.5; OR tertile 3 vs. 1 3.9; 95% CI 2.3-6.8).
Multivariate models
We ran three multivariate models (Table 4 ). The first model included only program-level factors, the second only contextual-level factors, the third combined both program-level and contextual-level factors that were significant in the prior two models. 
þ cell count (AOR 1.06 per unit increase; 95% CI 1.02-1.10). Finally, in model 3, which combined program-level and contextuallevel factors, all of the factors that were independently associated with low cohort median CD4 þ cell count in models 1 and 2 remained significant, with the exception of onsite vs. offsite PMTCT services and offsite vs. onsite CD4 þ testing. Independent of program and contextual factors, the odds of low cohort median CD4
þ cell count at ART initiation decreased with calendar time in doseresponse fashion.
Discussion
The findings from this analysis of CD4 þ cell count at ART initiation among cohorts included 121 504 patients from 267 public sector HIV care sites from eight sub Saharan African countries and demonstrated that a number of program-level factors were significantly associated with low median cohort CD4 þ cell counts at ART initiation. Program-level associations were independent of site characteristics (e.g., urban/rural, primary/secondary/tertiary), program burden (e.g., cohort size and provider-to-patient ratio), and context (e.g., AIDS awareness, testing coverage). The observed low median CD4 þ cell counts at ART initiation (i.e., with 25% of the cohorts in our sample having a median CD4 þ cell count of <111 cells/ml) are consistent with other reports from sub-Saharan Africa and further highlight the substantial amount of variability CD4 þ cell count at ART initiation across diverse sites and contexts. A number of program-level and contextuallevel factors were found to explain some of this variability and may represent important and potentially modifiable determinants of low CD4 þ cell count in populations of persons initiating ART.
The very high rates of late ART initiation in the region [2, 3] may in turn be driving early mortality after initiation of ART [4, 5] , and feasible upstream clinic and program- level interventions continue to be desperately needed. Our findings demonstrate a clear need to further investigate the role of upstream precursors and determinants of late ART initiation (e.g., late diagnosis, late engagement into care, and delayed ART initiation after eligibility determination) when designing HIV treatment programs. Specifically, we observed factors that may be related to the timeliness of diagnosis after infection (PMTCT affiliation, AIDS knowledge, and testing coverage), the willingness to engage into care given an HIV diagnosis (AIDS knowledge), and the timeliness of ART initiation given enrollment into care (availability of outreach, adherence support services provider-to-patient ratio). The latter finding may reflect better retention and ability to conduct clinical and immunologic monitoring to determine eligibility for ART.
With regard to the contextual-level factors examined, our analyses suggest that greater awareness of AIDS and higher testing coverage in the region are associated with lower risk of low CD4 þ cell count at ART initiation. These findings are encouraging to programs aimed at increasing awareness and knowledge of serostatus. However, the finding regarding awareness of HIV risk as measured by the proportion of persons in the population who believed that 'limiting themselves to one HIV-uninfected sexual partner reduces HIV risk' is unexpected and more difficult to interpret. It may reflect 'reverse causality' if, for example, greater efforts aimed at HIV prevention education are occurring in areas where HIV morbidity and mortality is highest, or where the epidemic is more mature. It could also reflect a false sense of security among some as yet undiagnosed HIV-infected individuals who perhaps do not fully Low CD4 cell count among ART initiation cohorts Nash et al. 1529 Table 3 . Crude odds ratio for contextual-level factors associated with low median CD4 cell counts among cohorts of patients initiating antiretroviral therapy. ART, antiretroviral therapy; CI, confidence interval.
appreciate their risk (which in turn could result in higher rates of delayed testing and diagnosis). Interestingly, we did not observe a similar association with knowledge around the need to use condoms to reduce HIV risk.
The risk of low median CD4 þ cell counts among cohorts of patients initiating ART declined with calendar time, possibly reflecting the effect of increasing HIV testing uptake among individuals in the community and ART availability [1] . In sub-Saharan Africa, HIV testing uptake is variable [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] , but generally, low throughout the region (e.g., 22% [1] ). That lower cohort size was associated with a higher likelihood of low cohort median CD4 þ cell count could reflect the startup of programs with newer sites initially focusing on initiation of ART among the sickest patients. As testing and ART coverage increase, the risk of late ART initiation would be expected to decrease. However, even in areas with relatively higher ART availability and coverage (e.g., the USA), there remain high rates of late diagnosis followed by delayed enrollment into care and consequently initiation of ART at lower CD4 þ cell counts. Approximately 26% of persons diagnosed with HIV in the USA [47] and in New York City [48] (the epicenter for HIV in the USA) have concomitant diagnosis of AIDS at the time of HIV diagnosis, and delayed access to HIV care after HIV diagnosis is common [49] [50] [51] . For example, a recent study in New York City showed that nearly 20% of newly diagnosed individuals had not yet enrolled in HIV care 1 year later [52] and this figure may be as high as 30-40% nationwide [49, 53, 54] . Thus, although there are encouraging reports of CD4 þ cell count at ART initiation increasing in the sub-Saharan African region [26] , without substantial expansion in HIV testing, increased efforts at engagement in care, and close clinical and immunological monitoring for ART eligibility, the challenge of late ART initiation may well persist.
The median CD4 þ cell count among cohorts of patients initiating ART was, on average, lower at urban sites compared with rural sites (131 vs. 155 cells/ml), and cohorts at urban sites were more than twice as likely to have low median CD4 þ cell count than those at rural sites (AOR 2.1; 95% CI 1.3-3.3). The reasons for this are not immediately clear and further investigation is needed. A few other studies in the region (from sites in Ghana and South Africa) have reported similar findings [55, 56] . There are plausible explanations as to why cohorts of patients initiating ART at urban clinics might be on an average sicker than those at rural clinics in some instances. Rural HIV epidemics are generally less mature in most areas than their urban counterparts [32, 57] , and there may be many more patients with very low CD4 þ cell count in urban than in rural areas. Additionally, similar to the spread of the HIVepidemic itself, HIV care and treatment scale-up in many sub-Saharan African countries started in large centers in urban areas before expanding to secondary and primary care sites in more rural areas [58] . Therefore, another possible explanation might be that many of the sickest patients in rural areas actually sought care and initiated ART in urban areas before HIV care clinics nearer to their homes became available. Moreover, sicker patients in rural areas may be more likely to go to a clinic in an urban area even if there is a clinic nearer to their home, perhaps because they believe the care to be better or because they are concerned about stigma in their community. Finally, HIV prevalence is generally lower in rural than in urban areas [32] and the patient load, even relative to staffing, may be substantially lower in rural clinics. This in turn could allow the sickest pool of patients to be treated more quickly in rural than in urban areas. Although we attempted to control for staffing ratios in a time-updated fashion, and these were found to be important correlates of low median CD4 þ cell count at ART initiation, staffing ratios are likely more complex than we were able to capture on our program survey, and ultimately control for in our analysis. Conversely, there are also plausible reasons why some cohorts of rural patients initiating ART might have lower median CD4 þ cell counts compared with urban patients, due, for example, to slower rollout of HIV care services compared with urban settings, lower HIV testing rates, and greater barriers associated with access such as longer distance to clinic, with costs and logistics of transport that may comparatively be more prohibitive [59] .
Strengths of our study included the use of routinely collected aggregate data used for monitoring and evaluation purposes, which allowed for the use of data for cohorts that included more than 120 000 patients starting ART in several sub-Saharan African countries.
The use of data from a diversity of sites, including rural and small sites and sites without electronic data systems, enhances the generalizability of our findings. The large number of clinics and contexts enabled us to examine a wide array of relevant program-level and contextual-level factors and control for confounding at each level. Our findings were robust to a number of sensitivity analyses, including the exclusion of individual countries (to examine the extent to which associations may be driven by sites in individual country), smaller cohorts (where median CD4 þ cell counts may be more variable and less informative), and cohorts that initiated ART in [2004] [2005] [2006] (to assess the influence of maturation of scale-up effect).
However, our study also has limitations requiring that the results be interpreted with caution. We examined the role of program and contextual factors that were observed, rather than randomly assigned (i.e., experimentally), and as such observed associations may be prone to confounding. Although we attempted to control for confounding by adjusting for measured factors hypothesized to be important, the associations we observed could be still be a result of uncontrolled confounding by other factors at the program and contextual levels. Finally, although a standard operating procedure on indicator definitions and limited quality assurance procedures help ensure consistency of reported indicators across sites and settings, data quality in the service delivery context is often limited and could have influenced our results (e.g., outcome misclassification). Further, the site surveys could have resulted in exposure misclassification. However, each misclassification is likely nondifferential with regard to one another, making it harder to observe true associations when they exist. In addition, site surveys elicited information on availability of specific services and not their coverage or utilization by patients at these particular sites. Further, although we used the most recent DHS data as source of our contextual-level data, these surveys were conducted from 2003 to 2005 and thus prior to the period during which most of our cohorts initiated ART (2007 and 2008) . Time-updated contextual-level information may have given different results. Finally, although our analysis included many rural sites (n ¼ 108), the proportion of patients from rural sites was small (15%) and may further limit generalizability. However, given the strength of the associations, future investigations should explore these areas further.
In conclusion, the associations observed in our analyses of factors associated with low CD4 þ cell count at ART initiation may represent potentially influential and modifiable determinants. Although the decreasing odds of low median CD4 þ cell count at ART initiation with calendar time is encouraging, a substantial proportion of cohorts continue to initiate ARTwith low median CD4 þ cell counts (e.g., 50% below 136 cells/ml). Our findings Low CD4 cell count among ART initiation cohorts Nash et al. 1531 suggest specific approaches that may motivate earlier ART initiation in populations of patients (e.g., development of interventions such as active tracing and tracking of patients in care who miss visits in order to ensure early identification of ART eligibility) and a need for more focused operational research on this issue.
